Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MPH Health Care AG (93M1.DE)
Berlin, DE
MPH Health Care AG is a German-based investment firm with a primary focus on the healthcare sector. The company's portfolio includes the production and distribution of medicinal products designed to treat serious illnesses like cancer, HIV, and various other chronic conditions. Beyond pharmaceuticals, it also delivers medical aesthetic treatments, develops and markets a diverse array of pharmaceutical and medical items, and furnishes related services and specialized medical devices for use in aesthetic surgery and cosmetic dermatology. Furthermore, its operations extend to supplying cytostatic solutions and involvement in real estate ventures. Established in Berlin in 2008, the company adopted its current name, MPH Health Care AG, in 2017, having previously been known as MPH Mittelständische Pharma Holding AG. It functions as a subsidiary of Magnum AG.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.38% | +1.93% | +25.12% | +18.39% | +23.36% | +19.46% | +42.70% | +65.00% | -2.94% | +1.15% | -22.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+5,860.8% ★ Q4'25: +4,916.9% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-8.6% Q4'25: +127.0% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.0% ★ Q4'25: +0.3% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+9.4% Q4'25: +29.9% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q4'25: +190.6% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q4'25: 0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×— Q4'25: 0.03× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
262.89M
est: 228.37M (+15.1%)
|
8.89M
est: 8.04M (+10.5%)
|
33.81M
est: 50.0K (+67,522.0%)
|
44.85M
est: 50.0K (+89,592.0%)
|
6.31M
est: 30.49M (-79.3%)
|
-9.02M
est: 1.89M (-576.5%)
|
4.36M
est: 44.84M (-90.3%)
|
6.85M
est: 8.13M (-15.7%)
|
7.24M
est: 118.24M (-93.9%)
|
6.11M
est: 81.03M (-92.5%)
|
364.30M
est: 68.60M (+431.0%)
|
29.12M
29.12M – 29.12M
-57.6% YoY
|
30.35M
30.35M – 30.35M
+4.2% YoY
|
| EBITDA |
14.05M
est: 137.02M (-89.7%)
|
79.37M
est: 4.83M (+1,544.8%)
|
33.08M
est: 30.0K (+110,166.7%)
|
37.69M
est: 30.0K (+125,518.5%)
|
11.60M
est: 18.29M (-36.6%)
|
-71.00M
est: 1.14M (-6,351.0%)
|
-9.05M
est: 26.90M (-133.7%)
|
29.68M
est: 4.88M (+508.4%)
|
30.36M
est: 70.95M (-57.2%)
|
33.32M
est: 48.62M (-31.5%)
|
34.10M
est: 41.16M (-17.2%)
|
17.47M
17.47M – 17.47M
-57.6% YoY
|
18.21M
18.21M – 18.21M
+4.2% YoY
|
| EBIT |
89.53M
est: 137.02M (-34.7%)
|
79.34M
est: 4.83M (+1,544.3%)
|
33.06M
est: 30.0K (+110,096.7%)
|
37.66M
est: 30.0K (+125,418.7%)
|
11.59M
est: 18.29M (-36.6%)
|
-71.02M
est: 1.14M (-6,352.5%)
|
-9.07M
est: 26.90M (-133.7%)
|
29.64M
est: 4.88M (+507.7%)
|
30.34M
est: 70.95M (-57.2%)
|
33.29M
est: 48.62M (-31.5%)
|
34.10M
est: 41.16M (-17.2%)
|
17.47M
17.47M – 17.47M
-57.6% YoY
|
18.21M
18.21M – 18.21M
+4.2% YoY
|
| Net Income |
82.59M
est: 5.99M (+1,277.9%)
|
80.07M
est: 37.68M (+112.5%)
|
31.86M
est: 26.97M (+18.1%)
|
37.02M
est: 21.84M (+69.6%)
|
11.08M
est: 36.82M (-69.9%)
|
-70.38M
est: -70.30M (-0.1%)
|
-8.96M
est: 40.59M (-122.1%)
|
29.11M
est: -9.42M (+409.1%)
|
29.54M
est: 119.46M (-75.3%)
|
32.04M
est: 76.20M (-58.0%)
|
29.30M
est: -29.11M (+200.6%)
|
25.26M
25.26M – 25.26M
+186.8% YoY
|
26.54M
26.54M – 26.54M
+5.1% YoY
|
| SGA |
8.33M
est: 27.71M (-70.0%)
|
558.0K
est: 975.9K (-42.8%)
|
1.18M
est: 6.1K (+19,300.0%)
|
1.15M
est: 6.1K (+18,789.1%)
|
933.7K
est: 3.70M (-74.8%)
|
841.5K
est: 229.7K (+266.3%)
|
923.3K
est: 5.44M (-83.0%)
|
987.2K
est: 986.6K (+0.1%)
|
1.14M
est: 14.35M (-92.0%)
|
1.14M
est: 9.83M (-88.4%)
|
—
est: 8.32M (-100.0%)
|
3.53M
3.53M – 3.53M
-57.6% YoY
|
3.68M
3.68M – 3.68M
+4.2% YoY
|
| EPS |
19.29
est: 1.40 (+1,277.9%)
|
18.70
est: 8.80 (+112.5%)
|
7.44
est: 6.30 (+18.1%)
|
8.65
est: 5.10 (+69.6%)
|
2.59
est: 8.60 (-69.9%)
|
-16.44
est: -16.42 (-0.1%)
|
-2.09
est: 9.48 (-122.0%)
|
6.80
est: -2.20 (+409.1%)
|
6.90
est: 27.91 (-75.3%)
|
7.48
est: 17.80 (-58.0%)
|
6.84
est: -6.80 (+200.6%)
|
5.90
5.90 – 5.90
+186.8% YoY
|
6.20
6.20 – 6.20
+5.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis International Equity ETF AVDE | 0.00% | 482.70 | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Patrick Brenske | Chief Executive Officer & Member of Management Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 93M1.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
